Efficacy and safety of combination therapy of natural human interferon β and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load

Yasuji Arase; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Yusuke Kawamura; Masahiro Kobayashi; Tetsuya Hosaka; Hiromi Yatsuji; Miharu Hirakawa; Naoki Matsumoto; Satoshi Saito; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada

doi:10.2169/internalmedicine.49.3299

Efficacy and safety of combination therapy of natural human interferon β and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load

Yasuji Arase, Fumitaka Suzuki, Norio Akuta, Hitomi Sezaki, Yoshiyuki Suzuki, Yusuke Kawamura, Masahiro Kobayashi, Tetsuya Hosaka, Hiromi Yatsuji, Miharu Hirakawa, Naoki Matsumoto, Satoshi Saito, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada

Toranomon Hospital

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Objective The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 2 and high virus load. Methods Inclusion criteria were HCV-genotype 2, serum HCV RNA level of ≥ 100 KIU/mL before combination therapy. A total of 24 were enrolled in this retrospective cohort study. The treatment period of combination therapy was 24 weeks. Results Of the 24 study patients, no patient stopped the treatment due to treatment-related adverse events. The dose of drugs were reduced in 8 patients. Twenty-one of 24 patients (87.5%) had sustained virological response (SVR) by the intention to treat analysis. The rate of negative HCV RNA at 8 week after the initiation of treatment was 18/21 (86%) in patients with SVR and 1/3 (33%) in patients with non-SVR. Logistic regression analysis showed that SVR occurred when serum HCV RNA at 8 week after the initiation of combination therapy was negative (hazard ratio: 40.0; 95% confidence interval=1.75-914.78; p=0.021) Conclusion The combination therapy of IFN-beta and ribavirin offers sufficient safety and efficacy in chronic hepatitis C patients with genotype 2 and high virus load.

Original language	English
Pages (from-to)	965-970
Number of pages	6
Journal	Internal Medicine
Volume	49
Issue number	11
DOIs	https://doi.org/10.2169/internalmedicine.49.3299
Publication status	Published - 2010
Externally published	Yes

Keywords

Chronic hepatitis C
HCV genotype 2
Natural interferon-beta
Ribavirin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.49.3299

Cite this

Arase, Y., Suzuki, F., Akuta, N., Sezaki, H., Suzuki, Y., Kawamura, Y., Kobayashi, M., Hosaka, T., Yatsuji, H., Hirakawa, M., Matsumoto, N., Saito, S., Ikeda, K., Kobayashi, M., & Kumada, H. (2010). Efficacy and safety of combination therapy of natural human interferon β and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load. Internal Medicine, 49(11), 965-970. https://doi.org/10.2169/internalmedicine.49.3299

@article{f90b6a7eb370443cb4f89a9d55dba257,

title = "Efficacy and safety of combination therapy of natural human interferon β and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load",

abstract = "Objective The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 2 and high virus load. Methods Inclusion criteria were HCV-genotype 2, serum HCV RNA level of ≥ 100 KIU/mL before combination therapy. A total of 24 were enrolled in this retrospective cohort study. The treatment period of combination therapy was 24 weeks. Results Of the 24 study patients, no patient stopped the treatment due to treatment-related adverse events. The dose of drugs were reduced in 8 patients. Twenty-one of 24 patients (87.5%) had sustained virological response (SVR) by the intention to treat analysis. The rate of negative HCV RNA at 8 week after the initiation of treatment was 18/21 (86%) in patients with SVR and 1/3 (33%) in patients with non-SVR. Logistic regression analysis showed that SVR occurred when serum HCV RNA at 8 week after the initiation of combination therapy was negative (hazard ratio: 40.0; 95% confidence interval=1.75-914.78; p=0.021) Conclusion The combination therapy of IFN-beta and ribavirin offers sufficient safety and efficacy in chronic hepatitis C patients with genotype 2 and high virus load.",

keywords = "Chronic hepatitis C, HCV genotype 2, Natural interferon-beta, Ribavirin",

author = "Yasuji Arase and Fumitaka Suzuki and Norio Akuta and Hitomi Sezaki and Yoshiyuki Suzuki and Yusuke Kawamura and Masahiro Kobayashi and Tetsuya Hosaka and Hiromi Yatsuji and Miharu Hirakawa and Naoki Matsumoto and Satoshi Saito and Kenji Ikeda and Mariko Kobayashi and Hiromitsu Kumada",

year = "2010",

doi = "10.2169/internalmedicine.49.3299",

language = "English",

volume = "49",

pages = "965--970",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "11",

}

Arase, Y, Suzuki, F, Akuta, N, Sezaki, H, Suzuki, Y, Kawamura, Y, Kobayashi, M, Hosaka, T, Yatsuji, H, Hirakawa, M, Matsumoto, N, Saito, S, Ikeda, K, Kobayashi, M & Kumada, H 2010, 'Efficacy and safety of combination therapy of natural human interferon β and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load', Internal Medicine, vol. 49, no. 11, pp. 965-970. https://doi.org/10.2169/internalmedicine.49.3299

TY - JOUR

T1 - Efficacy and safety of combination therapy of natural human interferon β and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load

AU - Arase, Yasuji

AU - Suzuki, Fumitaka

AU - Akuta, Norio

AU - Sezaki, Hitomi

AU - Suzuki, Yoshiyuki

AU - Kawamura, Yusuke

AU - Kobayashi, Masahiro

AU - Hosaka, Tetsuya

AU - Yatsuji, Hiromi

AU - Hirakawa, Miharu

AU - Matsumoto, Naoki

AU - Saito, Satoshi

AU - Ikeda, Kenji

AU - Kobayashi, Mariko

AU - Kumada, Hiromitsu

PY - 2010

Y1 - 2010

N2 - Objective The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 2 and high virus load. Methods Inclusion criteria were HCV-genotype 2, serum HCV RNA level of ≥ 100 KIU/mL before combination therapy. A total of 24 were enrolled in this retrospective cohort study. The treatment period of combination therapy was 24 weeks. Results Of the 24 study patients, no patient stopped the treatment due to treatment-related adverse events. The dose of drugs were reduced in 8 patients. Twenty-one of 24 patients (87.5%) had sustained virological response (SVR) by the intention to treat analysis. The rate of negative HCV RNA at 8 week after the initiation of treatment was 18/21 (86%) in patients with SVR and 1/3 (33%) in patients with non-SVR. Logistic regression analysis showed that SVR occurred when serum HCV RNA at 8 week after the initiation of combination therapy was negative (hazard ratio: 40.0; 95% confidence interval=1.75-914.78; p=0.021) Conclusion The combination therapy of IFN-beta and ribavirin offers sufficient safety and efficacy in chronic hepatitis C patients with genotype 2 and high virus load.

AB - Objective The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 2 and high virus load. Methods Inclusion criteria were HCV-genotype 2, serum HCV RNA level of ≥ 100 KIU/mL before combination therapy. A total of 24 were enrolled in this retrospective cohort study. The treatment period of combination therapy was 24 weeks. Results Of the 24 study patients, no patient stopped the treatment due to treatment-related adverse events. The dose of drugs were reduced in 8 patients. Twenty-one of 24 patients (87.5%) had sustained virological response (SVR) by the intention to treat analysis. The rate of negative HCV RNA at 8 week after the initiation of treatment was 18/21 (86%) in patients with SVR and 1/3 (33%) in patients with non-SVR. Logistic regression analysis showed that SVR occurred when serum HCV RNA at 8 week after the initiation of combination therapy was negative (hazard ratio: 40.0; 95% confidence interval=1.75-914.78; p=0.021) Conclusion The combination therapy of IFN-beta and ribavirin offers sufficient safety and efficacy in chronic hepatitis C patients with genotype 2 and high virus load.

KW - Chronic hepatitis C

KW - HCV genotype 2

KW - Natural interferon-beta

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=77953344980&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.49.3299

DO - 10.2169/internalmedicine.49.3299

M3 - Article

C2 - 20519810

AN - SCOPUS:77953344980

SN - 0918-2918

VL - 49

SP - 965

EP - 970

JO - Internal Medicine

JF - Internal Medicine

IS - 11

ER -

Efficacy and safety of combination therapy of natural human interferon β and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this